Antiretroviral  ||| S:0 E:15 ||| JJ
drug  ||| S:15 E:20 ||| NN
development  ||| S:20 E:32 ||| NN
for  ||| S:32 E:36 ||| IN
HIV ||| S:36 E:39 ||| NNP
:  ||| S:39 E:41 ||| :
challenges  ||| S:41 E:52 ||| NNS
for  ||| S:52 E:56 ||| IN
the  ||| S:56 E:60 ||| DT
future  ||| S:60 E:67 ||| NN
The  ||| S:67 E:71 ||| DT
scarcity  ||| S:71 E:80 ||| NN
of  ||| S:80 E:83 ||| IN
new  ||| S:83 E:87 ||| JJ
innovative  ||| S:87 E:98 ||| JJ
drugs  ||| S:98 E:104 ||| NNS
in  ||| S:104 E:107 ||| IN
the  ||| S:107 E:111 ||| DT
development  ||| S:111 E:123 ||| NN
pipeline  ||| S:123 E:132 ||| NN
for  ||| S:132 E:136 ||| IN
combating  ||| S:136 E:146 ||| VBG
HIV  ||| S:146 E:150 ||| NNP
replication  ||| S:150 E:162 ||| NN
may  ||| S:162 E:166 ||| MD
signal  ||| S:166 E:173 ||| VB
a  ||| S:173 E:175 ||| DT
change  ||| S:175 E:182 ||| NN
in  ||| S:182 E:185 ||| IN
direction  ||| S:185 E:195 ||| NN
for  ||| S:195 E:199 ||| IN
HIV  ||| S:199 E:203 ||| NNP
researchers  ||| S:203 E:215 ||| NNS
and  ||| S:215 E:219 ||| CC
drug  ||| S:219 E:224 ||| NN
developers ||| S:224 E:234 ||| NNS
.  ||| S:234 E:236 ||| .
The  ||| S:236 E:240 ||| DT
model  ||| S:240 E:246 ||| NN
of  ||| S:246 E:249 ||| IN
introducing  ||| S:249 E:261 ||| VBG
drugs  ||| S:261 E:267 ||| NNS
with  ||| S:267 E:272 ||| IN
incremental  ||| S:272 E:284 ||| JJ
improvements  ||| S:284 E:297 ||| NNS
within  ||| S:297 E:304 ||| IN
existing  ||| S:304 E:313 ||| VBG
drug  ||| S:313 E:318 ||| NN
classes  ||| S:318 E:326 ||| NNS
is  ||| S:326 E:329 ||| VBZ
no  ||| S:329 E:332 ||| RB
longer  ||| S:332 E:339 ||| RBR
commercially  ||| S:339 E:352 ||| RB
viable ||| S:352 E:358 ||| JJ
.  ||| S:358 E:360 ||| .
While  ||| S:360 E:366 ||| IN
an  ||| S:366 E:369 ||| DT
argument  ||| S:369 E:378 ||| NN
can  ||| S:378 E:382 ||| MD
be  ||| S:382 E:385 ||| VB
made  ||| S:385 E:390 ||| VBN
that  ||| S:390 E:395 ||| IN
drugs  ||| S:395 E:401 ||| NNS
aimed  ||| S:401 E:407 ||| VBN
at  ||| S:407 E:410 ||| IN
novel  ||| S:410 E:416 ||| NN
targets  ||| S:416 E:424 ||| NNS
may  ||| S:424 E:428 ||| MD
have  ||| S:428 E:433 ||| VB
a  ||| S:433 E:435 ||| DT
greater  ||| S:435 E:443 ||| JJR
impact ||| S:443 E:449 ||| NN
,  ||| S:449 E:451 ||| ,
the  ||| S:451 E:455 ||| DT
list  ||| S:455 E:460 ||| NN
of  ||| S:460 E:463 ||| IN
such  ||| S:463 E:468 ||| JJ
targets  ||| S:468 E:476 ||| NNS
is  ||| S:476 E:479 ||| VBZ
limited  ||| S:479 E:487 ||| VBN
and  ||| S:487 E:491 ||| CC
the  ||| S:491 E:495 ||| DT
scientific  ||| S:495 E:506 ||| JJ
challenge  ||| S:506 E:516 ||| NN
of  ||| S:516 E:519 ||| IN
intervening  ||| S:519 E:531 ||| VBG
at  ||| S:531 E:534 ||| IN
another  ||| S:534 E:542 ||| DT
stage  ||| S:542 E:548 ||| NN
in  ||| S:548 E:551 ||| IN
the  ||| S:551 E:555 ||| DT
HIV  ||| S:555 E:559 ||| NNP
replication  ||| S:559 E:571 ||| JJ
cycle  ||| S:571 E:577 ||| NN
is  ||| S:577 E:580 ||| VBZ
high ||| S:580 E:584 ||| JJ
.  ||| S:584 E:586 ||| .
It  ||| S:586 E:589 ||| PRP
is  ||| S:589 E:592 ||| VBZ
difficult  ||| S:592 E:602 ||| JJ
to  ||| S:602 E:605 ||| TO
envision  ||| S:605 E:614 ||| VB
a  ||| S:614 E:616 ||| DT
realistic  ||| S:616 E:626 ||| JJ
risk ||| S:626 E:630 ||| NN
/ ||| S:630 E:631 ||| CD
reward  ||| S:631 E:638 ||| NN
scenario  ||| S:638 E:647 ||| NN
that  ||| S:647 E:652 ||| WDT
will  ||| S:652 E:657 ||| MD
ensure  ||| S:657 E:664 ||| VB
continued  ||| S:664 E:674 ||| JJ
investment  ||| S:674 E:685 ||| NN
in  ||| S:685 E:688 ||| IN
the  ||| S:688 E:692 ||| DT
discovery  ||| S:692 E:702 ||| NN
of  ||| S:702 E:705 ||| IN
novel  ||| S:705 E:711 ||| NN
HIV  ||| S:711 E:715 ||| NN
drugs  ||| S:715 E:721 ||| NNS
that  ||| S:721 E:726 ||| WDT
simply  ||| S:726 E:733 ||| RB
block  ||| S:733 E:739 ||| VB
replication  ||| S:739 E:751 ||| NNS
and  ||| S:751 E:755 ||| CC
suppress  ||| S:755 E:764 ||| JJ
plasma  ||| S:764 E:771 ||| JJ
viral  ||| S:771 E:777 ||| JJ
load ||| S:777 E:781 ||| NN
.  ||| S:781 E:783 ||| .
Recently ||| S:783 E:791 ||| RB
,  ||| S:791 E:793 ||| ,
it  ||| S:793 E:796 ||| PRP
has  ||| S:796 E:800 ||| VBZ
been  ||| S:800 E:805 ||| VBN
suggested  ||| S:805 E:815 ||| VBN
that  ||| S:815 E:820 ||| IN
the  ||| S:820 E:824 ||| DT
scientific  ||| S:824 E:835 ||| JJ
community  ||| S:835 E:845 ||| NN
should  ||| S:845 E:852 ||| MD
move  ||| S:852 E:857 ||| VB
research  ||| S:857 E:866 ||| NN
in  ||| S:866 E:869 ||| IN
a  ||| S:869 E:871 ||| DT
new  ||| S:871 E:875 ||| JJ
direction ||| S:875 E:884 ||| NN
,  ||| S:884 E:886 ||| ,
with  ||| S:886 E:891 ||| IN
the  ||| S:891 E:895 ||| DT
goal  ||| S:895 E:900 ||| NN
of  ||| S:900 E:903 ||| IN
attacking  ||| S:903 E:913 ||| VBG
the  ||| S:913 E:917 ||| DT
reservoirs  ||| S:917 E:928 ||| NN
of  ||| S:928 E:931 ||| IN
latent  ||| S:931 E:938 ||| JJ
HIV  ||| S:938 E:942 ||| NN
that  ||| S:942 E:947 ||| WDT
persist  ||| S:947 E:955 ||| VBP
despite  ||| S:955 E:963 ||| IN
treatment  ||| S:963 E:973 ||| NN
with  ||| S:973 E:978 ||| IN
current  ||| S:978 E:986 ||| JJ
drugs  ||| S:986 E:992 ||| NNS
to  ||| S:992 E:995 ||| TO
achieve  ||| S:995 E:1003 ||| VB
a  ||| S:1003 E:1005 ||| DT
functional  ||| S:1005 E:1016 ||| JJ
cure ||| S:1016 E:1020 ||| NN
,  ||| S:1020 E:1022 ||| ,
if  ||| S:1022 E:1025 ||| IN
not  ||| S:1025 E:1029 ||| RB
a  ||| S:1029 E:1031 ||| DT
sterilizing  ||| S:1031 E:1043 ||| JJ
cure ||| S:1043 E:1047 ||| NN
.  ||| S:1047 E:1049 ||| .
This  ||| S:1049 E:1054 ||| DT
process  ||| S:1054 E:1062 ||| NN
will  ||| S:1062 E:1067 ||| MD
have  ||| S:1067 E:1072 ||| VB
to  ||| S:1072 E:1075 ||| TO
be  ||| S:1075 E:1078 ||| VB
a  ||| S:1078 E:1080 ||| DT
long-term  ||| S:1080 E:1090 ||| JJ
commitment ||| S:1090 E:1100 ||| NN
,  ||| S:1100 E:1102 ||| ,
primarily  ||| S:1102 E:1112 ||| RB
funded  ||| S:1112 E:1119 ||| VBN
by  ||| S:1119 E:1122 ||| IN
the  ||| S:1122 E:1126 ||| DT
NIH ||| S:1126 E:1129 ||| NNP
,  ||| S:1129 E:1131 ||| ,
with  ||| S:1131 E:1136 ||| IN
some  ||| S:1136 E:1141 ||| DT
involvement  ||| S:1141 E:1153 ||| NN
by  ||| S:1153 E:1156 ||| IN
the  ||| S:1156 E:1160 ||| DT
pharmaceutical  ||| S:1160 E:1175 ||| JJ
and  ||| S:1175 E:1179 ||| CC
biotechnology  ||| S:1179 E:1193 ||| NN
industries ||| S:1193 E:1203 ||| NNS
.  ||| S:1203 E:1205 ||| .
While  ||| S:1205 E:1211 ||| IN
most  ||| S:1211 E:1216 ||| JJS
individuals  ||| S:1216 E:1228 ||| NNS
infected  ||| S:1228 E:1237 ||| VBN
with  ||| S:1237 E:1242 ||| IN
HIV  ||| S:1242 E:1246 ||| NNP
can  ||| S:1246 E:1250 ||| MD
achieve  ||| S:1250 E:1258 ||| VB
viral  ||| S:1258 E:1264 ||| JJ
suppression  ||| S:1264 E:1276 ||| NN
with  ||| S:1276 E:1281 ||| IN
the  ||| S:1281 E:1285 ||| DT
current  ||| S:1285 E:1293 ||| JJ
approved  ||| S:1293 E:1302 ||| JJ
therapies ||| S:1302 E:1311 ||| NNS
,  ||| S:1311 E:1313 ||| ,
treatment  ||| S:1313 E:1323 ||| NN
is  ||| S:1323 E:1326 ||| VBZ
lifelong ||| S:1326 E:1334 ||| JJ
,  ||| S:1334 E:1336 ||| ,
side  ||| S:1336 E:1341 ||| NN
effects  ||| S:1341 E:1349 ||| NNS
are  ||| S:1349 E:1353 ||| VBP
significant  ||| S:1353 E:1365 ||| JJ
and  ||| S:1365 E:1369 ||| CC
resistance  ||| S:1369 E:1380 ||| NN
will  ||| S:1380 E:1385 ||| MD
eventually  ||| S:1385 E:1396 ||| RB
render  ||| S:1396 E:1403 ||| VB
more  ||| S:1403 E:1408 ||| JJR
of  ||| S:1408 E:1411 ||| IN
these  ||| S:1411 E:1417 ||| DT
drugs  ||| S:1417 E:1423 ||| NNS
less  ||| S:1423 E:1428 ||| RBR
effective ||| S:1428 E:1437 ||| JJ
.  ||| S:1437 E:1439 ||| .
New  ||| S:1439 E:1443 ||| NNP
and  ||| S:1443 E:1447 ||| CC
innovative  ||| S:1447 E:1458 ||| JJ
approaches  ||| S:1458 E:1469 ||| NNS
must  ||| S:1469 E:1474 ||| MD
be  ||| S:1474 E:1477 ||| VB
developed  ||| S:1477 E:1487 ||| VBN
to  ||| S:1487 E:1490 ||| TO
prevent  ||| S:1490 E:1498 ||| VB
viral  ||| S:1498 E:1504 ||| JJ
infection  ||| S:1504 E:1514 ||| NN
and  ||| S:1514 E:1518 ||| CC
further  ||| S:1518 E:1526 ||| RB
improve  ||| S:1526 E:1534 ||| VB
the  ||| S:1534 E:1538 ||| DT
quality  ||| S:1538 E:1546 ||| NN
of  ||| S:1546 E:1549 ||| IN
life  ||| S:1549 E:1554 ||| NN
for  ||| S:1554 E:1558 ||| IN
those  ||| S:1558 E:1564 ||| DT
individuals  ||| S:1564 E:1576 ||| NNS
who  ||| S:1576 E:1580 ||| WP
are  ||| S:1580 E:1584 ||| VBP
already  ||| S:1584 E:1592 ||| RB
infected ||| S:1592 E:1600 ||| VBN
.  ||| S:1600 E:1602 ||| .
